Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDAC + venetoclax arm in the ALLG AMLM26 INTERCEPT trial for progressive acute myeloid leukemia
ACTRN12624000006549Phase 2Recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of venetoclax and cytarabine in acute myeloid leukemia (AML), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: MRD clearance rate. Started Oct 2024; status: recruiting.
02
Drugs
venetoclaxcytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12624000006549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000006549.